Instil Bio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
TIL
- Investments
-
1
- Share Price
-
$5.55
- (As of Thursday Closing)
Instil Bio General Information
Description
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Contact Information
Website
www.instilbio.comCorporate Office
- 3963 Maple Avenue
- Suite 350
- Dallas, TX 75219
- United States
Corporate Office
- 3963 Maple Avenue
- Suite 350
- Dallas, TX 75219
- United States
Instil Bio Stock Performance
As of 19-Nov-2026, Instil Bio’s stock price is $5.55. Its current market cap is $37.6M with 6.78M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.55 | $5.43 | $5.14 - $13.50 | $37.6M | 6.78M | 41.2K | -$3.04 |
Instil Bio Financials Summary
As of 30-Sep-2026, Instil Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 66,844 | 79,852 | 89,571 | (47,628) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (17,248) | (69,658) | (69,515) | (155,939) |
| Net Income | (20,900) | (71,372) | (74,135) | (156,087) |
| Total Assets | 195,645 | 203,523 | 263,567 | 325,630 |
| Total Debt | 87,156 | 85,178 | 86,886 | 86,054 |
Instil Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Instil Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Instil Bio Comparisons
Industry
Financing
Details
Instil Bio Competitors (7)
One of Instil Bio’s 7 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Obsidian Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Instil Bio Patents
Instil Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024263890-A2 | Tumor-infiltrating lymphocyte (til) transduction methods | Inactive | 21-Jun-2023 | ||
| WO-2024263890-A3 | Tumor-infiltrating lymphocyte (til) transduction methods | Inactive | 21-Jun-2023 | ||
| WO-2024243429-A2 | Use of fusion constructs for cd4+ t cell therapy | Inactive | 24-May-2023 | ||
| WO-2024243429-A3 | Use of fusion constructs for cd4+ t cell therapy | Inactive | 24-May-2023 | ||
| WO-2024243428-A2 | Use of fusion constructs for cell therapy | Inactive | 24-May-2023 | C07K14/7051 |
Instil Bio Signals
Instil Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Instil Bio Acquisitions (1)
Instil Bio’s most recent deal was a Merger/Acquisition with Immetacyte for . The deal was made on 02-Mar-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immetacyte | 02-Mar-2020 | Merger/Acquisition | Drug Discovery |
Instil Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.46 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Instil Bio FAQs
-
When was Instil Bio founded?
Instil Bio was founded in 2018.
-
Where is Instil Bio headquartered?
Instil Bio is headquartered in Dallas, TX.
-
What is the size of Instil Bio?
Instil Bio has 17 total employees.
-
What industry is Instil Bio in?
Instil Bio’s primary industry is Biotechnology.
-
Is Instil Bio a private or public company?
Instil Bio is a Public company.
-
What is Instil Bio’s stock symbol?
The ticker symbol for Instil Bio is TIL.
-
What is the current stock price of Instil Bio?
As of 19-Nov-2026 the stock price of Instil Bio is $5.55.
-
What is the current market cap of Instil Bio?
The current market capitalization of Instil Bio is $37.6M.
-
Who are Instil Bio’s competitors?
Kite Pharma, Poseida Therapeutics, Obsidian Therapeutics, Iovance Biotherapeutics, and Adaptimmune Therapeutics are some of the 7 competitors of Instil Bio.
-
What is Instil Bio’s annual earnings per share (EPS)?
Instil Bio’s EPS for 12 months was -$3.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process